Results 1 to 10 of about 155 (115)

Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science
Major depressive disorder (MDD) imposes a substantial burden worldwide, with treatment‐resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior (MDSI) representing two of the most severe clinical challenges ...
Matthijs W. van Hoogdalem, Dong‐Jing Fu, Wayne C. Drevets, Peter N. Zannikos   +3 more
doaj   +4 more sources

Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database

Frontiers in Pharmacology
Esketamine nasal spray (ESK-NS) is a new drug for treatment-resistant depression, and we aimed to detect and characterize the adverse events (AEs) of ESK-NS using the Food and Drug Administration (FDA) adverse event reporting system (FAERS) database ...
Ruixue Liu, Chunxiao Liu, Dianwei Feng, Tongxin Guo, Ying Wang   +4 more
doaj   +5 more sources

Challenges for esketamine nasal spray in China: use and management

Frontiers in Pharmacology
Jianhong Wu, Jun Gu, Linghe Qiu, Xin Jin, Zhenhe Zhou   +4 more
doaj   +5 more sources

Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries

Middle East Current Psychiatry, 2023
Background There is a high unmet need among patients with treatment-resistant depression (TRD) as treatment with standard therapies is associated with low response and remission rates and high rates of relapse.
Nahida Nayaz Ahmed, Faisal Albishi, Suhail A. Khan, Ammar Alsayegh, Emmanuel Stip, Samer Makhoul   +5 more
doaj   +2 more sources

Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report [PDF]

Annals of General Psychiatry, 2020
Background Patients with depression who are treated with esketamine nasal spray may commonly experience dysgeusia (bad/metallic/bitter taste) and related side effects such as nausea and vomiting.
Nicholas A. Bossaller, Richard C. Shelton   +1 more
doaj   +3 more sources

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report [PDF]

Therapeutic Advances in Psychopharmacology, 2021
Functional neurological disorder (FND) is a complex neuropsychiatric condition characterized by the presence of neurological symptoms and signs (either motor or sensory) that cannot be explained by any known medical or mental disease.
Júlia Vendrell-Serres, Óscar Soto-Angona, Amanda Rodríguez-Urrutia, Gara Arteaga-Henríquez, Josep A. Ramos-Quiroga   +4 more
doaj   +4 more sources

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

Frontiers in Psychiatry, 2023
BackgroundThe efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to a newly initiated selective serotonin reuptake ...
Albino J. Oliveira-Maia, Albino J. Oliveira-Maia, Benoit Rive, Joachim Morrens, Yordan Godinov, Jedelyn Cabrieto, Nolen Perualila, Siobhán Mulhern-Haughey   +7 more
doaj   +3 more sources

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry

Frontiers in Psychiatry, 2023
BackgroundTreatment resistant depression (TRD) affects 10–30% of patients with major depressive disorder. In 4-week trials, esketamine nasal spray (NS) was efficacious vs.
Albino J. Oliveira-Maia, Albino J. Oliveira-Maia, Joachim Morrens, Benoit Rive, Yordan Godinov, Jedelyn Cabrieto, Nolen Perualila, Sebastien Barbreau, Siobhán Mulhern-Haughey   +8 more
doaj   +3 more sources

Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States [PDF]

Psychiatric Services, 2020
This study aimed to estimate the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant, for patients in the United States with treatment-resistant depression.A decision-analytic model parameterized with efficacy data from phase 3 randomized trials of esketamine was used to simulate the effects of treatment with esketamine versus ...
Djora Soeteman
exaly   +3 more sources

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression

International Journal of Neuropsychopharmacology
Abstract Background Esketamine nasal spray (ESK) is approved, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression in adults and for the treatment of depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
Gérard Sanacora, Sanacora Gérard
exaly   +3 more sources